Starting HRT: What to Expect in the First Weeks and Months

The short answer

That is the honest shape of the answer: a staggered sequence, not a countdown. Anyone giving you a precise week-by-week schedule is inventing it. Individual response varies with the dose you were started on, the route it is delivered by, how well you absorb it, whether the symptom you are tracking is actually estrogen-responsive, and how severe things were at baseline. What is predictable is the order, the fact that the first weeks include a settling-in period with side effects that commonly fade, and the fact that unscheduled bleeding is common early on but has rules about when it stops being expected.

The practical framing that helps most: treat the first stretch as a calibration period, not a verdict. Starting dose is a starting point. NAMS advises using the lowest effective dose for the individual, which by definition means finding out what effective looks like for you — and that requires one or more adjustments in many women. "It's not working" almost always resolves into one of four things: the dose is too low, the route is wrong for your absorption or risk profile, not enough time has passed for that particular symptom, or you are measuring a symptom that estrogen was never going to fix.

The realistic sequence: which symptoms move first

The most useful mental model is a queue. Vasomotor symptoms — hot flashes, night sweats, flushing — sit at the front because they are the symptom estrogen acts on most directly. NAMS 2022 positions hormone therapy as the most effective treatment available for these, and in practice they are the symptom women notice changing first.

Sleep sits in the middle of the queue and is genuinely two problems wearing one coat. Some of your poor sleep is caused by night sweats waking you; that portion improves as vasomotor symptoms settle. Some of it is independent insomnia, restless sleep, or a sleep disorder that predates menopause, and that portion will not resolve just because estrogen is on board. This is the single most common reason women feel their HRT is underperforming — the hot flashes did improve, but the sleep problem that remains was never the same problem.

Mood, irritability, low motivation and the concentration complaints often described as brain fog are later and softer still. Improvement here is real for many women but is often indirect: better sleep and fewer disruptive symptoms improve mood, rather than estrogen acting as an antidepressant. ACOG's patient guidance on the menopause years frames mood changes in this period as having several possible causes, which is why a clinician may explore sleep, thyroid, life stressors and depression alongside hormones rather than assuming the hormones will handle it.

Genitourinary symptoms are at the back of the queue and behave differently from everything else. The NAMS 2020 genitourinary syndrome of menopause position statement describes GSM as chronic and progressive, unlike vasomotor symptoms, which often subside over time on their own. It does not tend to improve spontaneously, and it frequently does not improve adequately on systemic doses aimed at hot flashes.

Vasomotor symptoms: your clearest early signal

If you want one thing to track in the early weeks, track hot flashes and night sweats. They are the symptom with the tightest link to systemic estrogen, so they are the best available read on whether your dose and route are doing anything at all. NAMS 2022 identifies hormone therapy as the most effective treatment for vasomotor symptoms, which is why clinicians use them as the practical dose-titration signal.

Improvement usually shows up as a change in pattern before a change in count. Flashes get shorter, less intense, less drenching, or stop hijacking your sleep, before they stop happening. Judging success purely by whether they have vanished sets an unrealistic bar and can make a working dose look like a failed one.

Keep a rough tally rather than a precise one: a note of how many disruptive episodes you had each day and how many times you woke at night sweating. Two lines a day is enough. This is the single most useful thing you can bring to a follow-up appointment, because it converts "I don't think it's working" into something your prescriber can act on.

Also worth knowing: NAMS 2020 notes that vasomotor symptoms often subside over time on their own, whereas genitourinary symptoms do not. That distinction matters when you and your clinician later discuss how long to continue therapy and what it is still doing for you.

Sleep: the symptom most often misread

Sleep improvement on HRT is frequently real but frequently misattributed. If night sweats were fragmenting your sleep, resolving them tends to restore sleep continuity without estrogen doing anything to sleep architecture directly. If you had trouble falling asleep, early-morning waking, or unrefreshing sleep before menopause, those are separate problems and they typically persist.

The diagnostic question to ask yourself is simple: when I wake at night now, am I sweating? If yes, the vasomotor symptom is still incompletely treated and dose or route is the conversation. If you are waking dry, alert, or anxious, you are looking at insomnia that deserves its own assessment rather than more estrogen.

This distinction is worth raising explicitly at follow-up. Escalating an estrogen dose to chase a sleep problem that is not vasomotor in origin exposes you to more hormone without a matching benefit, which runs against the NAMS 2022 principle of using the lowest dose that achieves the treatment goal.

Sleep apnea, restless legs, thyroid dysfunction, alcohol timing and untreated anxiety all worsen sleep in this age band and none respond to hormone therapy. A prescriber who asks about snoring, witnessed apneas, or a thyroid check when you report ongoing poor sleep is doing the right thing, not deflecting.

Genitourinary symptoms: why systemic HRT often is not enough

Vaginal dryness, burning, painful sex, urinary urgency and recurrent urinary tract infections are grouped as genitourinary syndrome of menopause. The NAMS 2020 position statement on GSM describes it as chronic and progressive, and — critically — as something that commonly requires treatment directed at the tissue itself. Many women on a systemic patch or pill still have genitourinary symptoms, because doses chosen to control hot flashes are not necessarily sufficient for vaginal and urethral tissue.

This is the most common form of "my HRT isn't working" that is actually a targeting problem rather than a dose problem. The systemic therapy may be doing exactly what it was prescribed to do. The genitourinary symptoms need a different tool.

NAMS 2020 describes a treatment ladder for GSM: non-hormonal vaginal moisturizers and lubricants for milder symptoms, and low-dose vaginal estrogen or other local prescription options when those are insufficient. NAMS 2022 also notes that low-dose vaginal estrogen used for genitourinary symptoms alone does not carry the same requirement for a progestogen that systemic estrogen does in a woman with a uterus — a point worth clarifying with your prescriber rather than assuming.

Response here is slow by nature. Tissue change is not a switch. Improvement in dryness and comfort with penetration tends to build gradually, and urinary symptoms often trail vaginal ones. Judging local therapy after a very short trial is the most common way women wrongly conclude it failed.

Raise these symptoms by name at follow-up. They are systematically under-reported — many women mention hot flashes and never mention pain with sex or urinary urgency, and appointments are short enough that a clinician may not ask.

The settling-in period: side effects that usually fade

The first stretch on HRT often feels worse before it feels better in specific, recognizable ways. Breast tenderness or fullness, bloating, nausea, mild headache, and a general sense of the body noticing something changed are the classic early complaints. In many women these ease as the body adjusts to a steady hormone level.

This matters because the settling-in period is when most women quit. Stopping during the first weeks means you never find out whether the therapy would have worked, and it means the next conversation with your prescriber starts from zero rather than from useful information.

The distinction to hold onto: side effects that are easing week over week are usually settling in. Side effects that are stable or worsening, or that are severe enough to interfere with daily life, are a signal to contact the prescriber about dose or formulation — not a signal to endure indefinitely.

Some early effects are not settling-in effects at all and need prompt attention rather than patience. New severe headache, calf pain or swelling, chest pain or breathlessness, and visual disturbance are in a different category entirely; those belong in the red-flag list below, not on a wait-and-see plan.

Practical adjustments sometimes solve what looks like intolerance. Breast tenderness may respond to a lower estrogen dose. Nausea is sometimes an oral-route issue that improves on a transdermal patch or gel. Progestogen-related low mood or bloating can sometimes be addressed by changing the type of progestogen or the regimen. None of these are things to work out alone.

Breakthrough bleeding: what is expected and what is not

Unscheduled bleeding and spotting are common in the early months of hormone therapy, particularly on continuous combined regimens, and this is anticipated rather than alarming in itself. The endometrium is adjusting to a new hormonal environment, and an irregular pattern before things settle is a recognized part of that.

That said, bleeding is the one area where you should not self-diagnose. ACOG's patient guidance on perimenopausal bleeding and bleeding after menopause is unambiguous that bleeding after menopause needs evaluation. "I'm on HRT" is a plausible explanation, not a confirmed one, and it is not a reason to skip assessment of bleeding that is heavy, prolonged, persistent beyond the expected settling period, or that starts after a stretch of no bleeding.

When bleeding is evaluated, transvaginal ultrasound is a common first step. The ACOG committee opinion on the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding describes its use in this setting, including the reassurance value of a thin endometrial stripe and the circumstances where further evaluation such as endometrial sampling is warranted. Your prescriber decides which pathway fits; the point for you is that an imaging or sampling recommendation is routine practice, not evidence that something has been found.

The reverse situation also comes up. Incidental endometrial thickening found on a scan done for some other reason, in a woman with no bleeding, is a different clinical question. The 2024 SOGC guideline on asymptomatic endometrial thickening in postmenopausal women addresses exactly this scenario and how it should be approached, and it is a reasonable thing to ask about if a scan report worries you but you have had no bleeding at all.

If you have a uterus and are on systemic estrogen, the progestogen component is what protects the endometrium — NAMS 2022 is explicit that estrogen alone is not appropriate in a woman with an intact uterus. Skipping progestogen doses, or quietly stopping it because of side effects, is one of the more consequential things that can go wrong early. If the progestogen is the problem, that is a conversation, not a unilateral decision.

Why dose gets adjusted — and why that is not failure

Starting doses are estimates. NAMS 2022 frames therapy around using an appropriate dose and route for the individual, with the lowest effective dose consistent with treatment goals — which means the correct dose is defined by your response, and your response cannot be known before you respond.

Dose goes up when vasomotor symptoms remain disruptive after a fair trial and there is no indication that absorption or adherence is the issue. Dose goes down when side effects like breast tenderness are persistent, or when symptoms are well controlled and the goal shifts to maintaining control on the least hormone necessary.

Adjustment is not evidence that the first prescription was wrong. It is how titration works in every area of medicine that titrates. Women who expect one prescription to be final are the ones most likely to interpret a normal adjustment as a failed treatment and drop out.

One caution: give each change a fair trial before judging it. Chasing symptoms with rapid changes makes it impossible to know what worked. Your prescriber will usually specify an interval before reassessment — that interval exists so the signal is interpretable.

Route matters: patch, gel, spray, pill, and vaginal

Route is not a preference detail. It changes absorption, it changes the consistency of your hormone levels, and it changes the risk profile. NAMS 2022 discusses transdermal estrogen as an option associated with lower risk of venous thromboembolism and stroke than oral estrogen, which is a key reason route is individualized rather than defaulted.

Absorption differences are also an under-recognized cause of apparent non-response. A patch that repeatedly loosens, comes off in the shower, or is applied to an unsuitable site delivers less than intended. Gel applied inconsistently, applied to the wrong area, or washed off shortly after application does the same. Before concluding a dose is too low, it is worth confirming that the dose is actually getting in.

Vaginal preparations are a different category with a different job. Low-dose vaginal estrogen is aimed at genitourinary tissue rather than at hot flashes, and NAMS 2020 positions it within the treatment ladder for genitourinary syndrome of menopause. Being on a systemic patch does not automatically mean genitourinary symptoms are covered, and using a local product does not mean you are doubling up inappropriately — that is a specific question for your prescriber.

Route may also change for reasons that have nothing to do with symptom control: personal or family history relevant to clotting risk, other medications, skin reactions to adhesive, migraine history, or simple practicality. A route change mid-course is normal management.

"It's not working" — the four things it usually means

When symptoms have not improved, it is almost never a mystery. It resolves into one of four categories, and each has a different fix. Working out which one you are in before your appointment makes that appointment far more productive.

Dose too low: vasomotor symptoms remain disruptive, you are taking the therapy consistently, and nothing about absorption looks off. This is the straightforward titration conversation.

Wrong route: you are having side effects tied to the route, such as nausea on an oral preparation, or you have a risk profile that makes another route preferable, or the current route does not suit your skin or routine.

Absorption or adherence: patches not staying on, gel applied inconsistently, doses missed, or a regimen that does not fit your life. This looks identical to "dose too low" from the outside and is treated completely differently.

Wrong target symptom: the thing you are measuring was never going to respond to systemic estrogen. Non-vasomotor insomnia, depression, thyroid dysfunction, and genitourinary symptoms needing local therapy all live here. This is the category most often mistaken for treatment failure, and increasing the estrogen dose does not fix any of it.

The progestogen half of the regimen

If you have a uterus and are taking systemic estrogen, a progestogen is not optional. NAMS 2022 is explicit that estrogen therapy alone is inappropriate for women with an intact uterus, because unopposed estrogen increases the risk of endometrial hyperplasia and cancer. The progestogen is what prevents that.

Progestogen is also a common source of early side effects that get blamed on the estrogen: low mood, bloating, breast tenderness, or a premenstrual-like feeling, sometimes clustering at a predictable point in a cyclical regimen. If you notice a pattern tied to timing rather than a constant background effect, say so — that pattern is diagnostically useful.

There is more than one progestogen and more than one regimen. Cyclical regimens produce a scheduled bleed; continuous combined regimens aim for no bleeding after an initial settling period, which is why unscheduled bleeding is more expected early on continuous regimens. Which one suits you depends on where you are relative to your final period and what your prescriber is trying to achieve.

The important behavioral point: never drop the progestogen on your own while continuing estrogen. If it is causing problems, the fix is a different progestogen, a different dose, or a different regimen — decided with the prescriber, not by omission.

When to go back to your prescriber

Go back at the interval you were given, even if things are going well — that appointment is where dose is confirmed rather than guessed at, and where anything you have not mentioned gets caught.

Go back sooner if vasomotor symptoms have not meaningfully changed after a fair trial at the current dose, if side effects are stable or worsening rather than easing, or if you are considering stopping. Stopping without a conversation is the outcome most worth avoiding, because it leaves both of you without information.

Go back specifically about bleeding that is heavy, prolonged, persistent past the settling period, or that appears after a stretch of no bleeding at all — ACOG's guidance is that bleeding after menopause warrants evaluation, and being on hormone therapy does not exempt you from that.

Go back about genitourinary symptoms even if you are otherwise happy with your therapy. These are chronic and progressive per NAMS 2020 and they do not fix themselves; there are treatments specifically for them that you may not currently be on.

Bring your notes. The tally of disruptive hot flashes, the record of night wakings, the bleeding dates, and whether side effects are easing or not — those turn a vague appointment into a decision.

Setting expectations you can actually hold

A realistic frame for the first months: expect the earliest change in hot flashes and night sweats, expect sleep and mood to follow more slowly and less completely, expect genitourinary symptoms to need their own treatment and their own patience, and expect at least the possibility of a dose or route adjustment along the way.

What not to expect: a uniform timeline, a return to a pre-menopausal baseline in every domain, or a single prescription that resolves everything you have been experiencing. Some symptoms attributed to menopause have other causes, and ACOG's menopause patient guidance reflects that this life stage overlaps with thyroid disease, depression, sleep disorders and other conditions that need their own assessment.

Hormone therapy is also not a permanent, unrevisited decision. NAMS 2022 frames it as an individualized decision, periodically reassessed, weighing your symptoms, your age, your time since menopause and your personal risk profile. The follow-up conversations are part of the treatment, not a sign it is going badly.

This site does not sell or prescribe anything. If you are comparing providers or working out what a telehealth menopause service offers versus in-person care, compare providers on their own terms — what they prescribe, whether they offer local vaginal options, how follow-up and dose adjustment are handled, and how they evaluate bleeding.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• My hot flashes have not changed much on this dose — is the next step a higher dose, a different route, or something else entirely?
• I am still waking at night, but I wake dry rather than sweating. Could this be a separate sleep problem that needs its own assessment?
• I still have vaginal dryness and pain with sex on my current therapy. Would adding a low-dose vaginal estrogen or another local treatment be appropriate for me?
• My patch keeps coming off before it is due to change — could that be why my symptoms have not improved, and should we change route?
• The side effects I get seem to cluster around the progestogen rather than being constant. Can we change the type of progestogen or the regimen?
• I have had some spotting since starting. Does this need to be evaluated, or is it within what you would expect at this stage?
• When should I come back, and what specifically do you want me to be tracking between now and then?

Frequently asked questions

How long until HRT starts working?

There is no single answer, and any source giving you a precise week count is inventing it. What is consistent is the order: hot flashes and night sweats respond earliest and most reliably, since NAMS 2022 identifies hormone therapy as the most effective treatment for vasomotor symptoms. Sleep and mood improve later and often indirectly. Vaginal dryness, pain with sex and urinary symptoms are the slowest and frequently need local vaginal treatment rather than more systemic dose. Track disruptive hot flashes daily — it is the clearest early signal that the dose and route are doing something.

Is breakthrough bleeding normal when starting HRT?

Unscheduled bleeding and spotting are common in the early months, particularly on continuous combined regimens, as the endometrium adjusts. But ACOG is clear that bleeding after menopause warrants evaluation, and being on hormone therapy is not a reason to skip that. Report bleeding that is heavy, prolonged, continues past the expected settling period, or that starts after a stretch of no bleeding. Evaluation commonly begins with transvaginal ultrasound; ACOG's committee opinion describes its role in assessing the endometrium in women with postmenopausal bleeding, including when further sampling is appropriate.

My hot flashes improved but I still sleep badly. Is the HRT failing?

Probably not — you likely have two separate problems. Sleep disruption caused by night sweats improves as vasomotor symptoms settle. Insomnia that exists independently does not respond to estrogen. The diagnostic question is whether you wake sweating or wake dry. If you wake dry and alert, ask your prescriber about screening for sleep apnea, thyroid dysfunction, depression and primary insomnia rather than pushing the estrogen dose higher, which exposes you to more hormone without addressing the actual cause.

Why is my vaginal dryness not improving on my patch?

Because systemic doses chosen to control hot flashes are frequently not sufficient for vaginal and urethral tissue. The NAMS 2020 position statement describes genitourinary syndrome of menopause as chronic and progressive, and outlines treatment aimed locally: non-hormonal moisturizers and lubricants for milder symptoms, and low-dose vaginal estrogen or other local prescription options when those are inadequate. This is a targeting problem, not a treatment failure. Raise it by name at follow-up — genitourinary symptoms are heavily under-reported and short appointments often do not cover them unless you bring them up.

Should I stop HRT if I feel worse in the first weeks?

Not without talking to your prescriber, unless you have a red-flag symptom. Breast tenderness, bloating, mild nausea and headache are common settling-in effects that often ease as your body adjusts to a steady hormone level. Side effects that are easing week over week generally represent settling in; side effects that are stable, worsening, or interfering with daily life warrant a conversation about dose or formulation. Stopping silently means you never learn whether the therapy would have worked, and your next appointment starts from nothing.

Why did my prescriber change my dose or switch me to a patch?

Because starting doses are estimates and route is individualized. NAMS 2022 frames therapy around the lowest effective dose for the individual, which can only be identified by observing your response. Route also carries different risk: NAMS 2022 discusses transdermal estrogen as associated with lower risk of venous thromboembolism and stroke than oral estrogen, so a switch may reflect your risk profile rather than a symptom problem. A switch can also solve route-specific side effects such as nausea on an oral preparation. Adjustment is normal titration, not evidence the first prescription was a mistake.

Do I still need progestogen if I only use vaginal estrogen?

These are different situations and you should confirm yours with your prescriber. NAMS 2022 states that estrogen alone is inappropriate for a woman with an intact uterus taking systemic estrogen, because unopposed estrogen raises the risk of endometrial hyperplasia and cancer — a progestogen is required. NAMS 2022 addresses low-dose vaginal estrogen used for genitourinary symptoms separately, noting it does not carry that same progestogen requirement. Never stop a prescribed progestogen on your own while continuing systemic estrogen; if it causes side effects, ask about changing the type, dose or regimen instead.

What should I bring to my HRT follow-up appointment?

Five things, and they take two lines a day to collect: a daily count of disruptive hot flashes, the number of times you woke at night and whether you were sweating, dates and character of any bleeding, whether side effects are easing or not, and a note on any vaginal or urinary symptoms. Also flag practical problems — patches falling off early, missed doses, inconsistent gel application — because absorption problems look identical to an inadequate dose from the outside and are managed completely differently.

A scan showed a thickened endometrium but I have no bleeding. What does that mean?

Thickening found incidentally, in a woman with no bleeding, is a different clinical question from thickening found during evaluation of postmenopausal bleeding. The 2024 SOGC guideline addresses asymptomatic endometrial thickening in postmenopausal women specifically and how it should be approached. Bring the report to your prescriber and ask them to explain which situation applies to you and what, if anything, follows. Do not extrapolate from guidance written about women who are bleeding.

How long do vasomotor symptoms last if I do nothing?

NAMS 2020 notes that vasomotor symptoms often subside over time on their own, which is a genuine difference from genitourinary syndrome of menopause — described in the same statement as chronic and progressive, without spontaneous resolution. That distinction matters for how you think about duration of treatment: hot flashes may eventually settle without therapy, whereas vaginal and urinary symptoms typically will not. Duration of any hormone therapy is an individualized decision, periodically reassessed with your prescriber against your symptoms, age, time since menopause and risk profile.

Primary sources

1. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
2. The 2020 genitourinary syndrome of menopause position statement of NAMS. Menopause, 2020. PMID 32852449.
3. ACOG: The Menopause Years (patient FAQ).
4. ACOG: Perimenopausal Bleeding and Bleeding After Menopause (patient FAQ).
5. ACOG Committee Opinion: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding.
6. Guideline No. 451: Asymptomatic Endometrial Thickening in Postmenopausal Women. J Obstet Gynaecol Can, 2024. PMID 38901794.